Cutaneous porphyrias part II: Treatment strategies

International Journal of Dermatology

Volumn 53, Issue 1, 2014, Pages 3-24

  Tintle, Suzanne ^a   Alikhan, Ali ^b   Horner, Mary E ^c   Hand, Jennifer L ^b   Davis, Dawn Marie R ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AFAMELANOTIDE; ALPHA INTERMEDIN DERIVATIVE; ALPHA TOCOPHEROL; BETA CAROTENE; CHLOROQUINE; CYSTEINE; HYDROXYCHLOROQUINE; PORPHOBILINOGEN SYNTHASE;

ACUTE INTERMITTENT PORPHYRIA; ALTERNATIVE MEDICINE; ANALGESIA; BONE MARROW TRANSPLANTATION; CHILDHOOD DISEASE; CONGENITAL ERYTHROPOIETIC PORPHYRIA; COPROPORPHYRIA; DISEASE EXACERBATION; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIC PROTOPORPHYRIA; HEMOCHROMATOSIS; HEPATOERYTHROPOIETIC PORPHYRIA; HUMAN; IRON CHELATION; KIDNEY DISEASE; LIGHT; LIVER DISEASE; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; OSTEODYSTROPHY; PHLEBOTOMY; PORPHYRIA VARIEGATA; PROGNOSIS; REVIEW; SKELETON MALFORMATION; SUNLIGHT PROTECTION; ULTRAVIOLET RADIATION;

HUMANS; PHOTOSENSITIVITY DISORDERS; PORPHYRIAS; SKIN DISEASES; SUNLIGHT;

EID: 84890790522     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12016     Document Type: Review

References (227)

1. Lecha M, Herrero C, Ozalla D. Diagnosis and treatment of the hepatic porphyrias. Dermatol Ther 2003; 16: 65-72.
2. Holme SA, Anstey AV, Badminton MN, et al. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. Br J Dermatol 2008; 159: 211-213.
3. Murphy GM. Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther 2003; 16: 57-64.
4. Antoniou C, Kosmadaki MG, Stratigos AJ, et al. Sunscreens - what's important to know. J Eur Acad Dermatol Venereol 2008; 22: 1110-1118.
5. Dawe SA, Peters TJ, Du Vivier A, et al. Congenital erythropoietic porphyria: dilemmas in present day management. Clin Exp Dermatol 2002; 27: 680-683.
6. Diffey BL, Farr PM. Sunscreen protection against UVB, UVA and blue light: an in vivo and in vitro comparison. Br J Dermatol 1991; 124: 258-263.
7. Harada FA, Shwayder TA, Desnick RJ, et al. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol 2001; 45: 279-282.
8. Chatelain E, Gabard B. Photostabilization of butyl methoxydibenzoylmethane (Avobenzone) and ethylhexyl methoxycinnamate by bis-ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S), a new UV broadband filter. Photochem Photobiol 2001; 74: 401-406.
9. Johnson JA, Fusaro RM. Protection against long ultraviolet radiation: topical browning agents and a new outlook. Dermatologica 1987; 175: 53-57.
10. Asawanonda P, Oberlender S, Taylor C. The use of dihydroxyacetone for photoprotection in variegate porphyria. Int J Dermatol 1999; 38: 916-918.
11. Nuzum-Keim AD, Sontheimer RD. Ultraviolet light output of compact fluorescent lamps: comparison to conventional incandescent and halogen residential lighting sources. Lupus 2009; 18: 556-560.
12. Mazza JM, Zippin JH. Alpha-melanocyte stimulating hormone analogs: the perils and the promise. J Drugs Dermatol 2009; 8: 772-776.
13. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A 1980; 77: 5754-5758.
14. Harms J, Lautenschlager S, Minder SE, et al. An alpha-melanocyte-stimulating hormone analog in erythropoietic protoporphyria. N Engl J Med 2009; 360: 306-307.
15. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006; 126: 1869-1878.
16. Fitzgerald LM, Fryer JL, Dwyer T, et al. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006; 27: 388-394.
17. Cardones AR, Grichnik JM. Alpha-melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol 2009; 145: 441-444.
18. Langan EA, Ramlogan D, Jamieson LA, et al. Change in moles linked to use of unlicensed "sun tan jab". BMJ 2009; 338: 277.
19. Harms JH, Lautenschlager S, Minder CE, et al. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009; 85: 1434-1439.
20. Minder EI. 4Nle-D-7Phe-alpha-melanocyte-stimulating hormone to treat congenital erythropoietic and hepatoerythropoietic porphyria: an open-label compassionate use application. In: 2009 Conference of the American Academy of Dermatology, March 6-10, 2009, San Francisco, CA; AB155.
21. Topi GC, Amantea A, Griso D. Recovery from porphyria cutanea tarda with no specific therapy other than avoidance of hepatic toxins. Br J Dermatol 1984; 111: 75-82.
22. Sarkany RP. The management of porphyria cutanea tarda. Clin Exp Dermatol 2001; 26: 225-232.
23. Egger NG, Goeger DE, Payne DA, et al. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002; 47: 419-426.
24. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010; 52: 252-257.
25. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
26. Ramsay CA, Magnus IA, Turnbull A, et al. The treatment of porphyria cutanea tarda by venesection. Q J Med 1974; 43: 1-24.
27. Sommer S, Wilkinson SM. Porphyria cutanea tarda masquerading as chronic hand eczema. Acta Derm Venereol 2004; 84: 170-171.
28. Byrne JP, Boss JM, Dawber RP. Contraceptive pill-induced porphyria cutanea tarda presenting with onycholysis of the finger nails. Postgrad Med J 1976; 52: 535-538.
29. Haberman HF, Rosenberg F, Menon IA. Porphyria cutanea tarda: comparison of cases precipitated by alcohol and estrogens. Can Med Assoc J 1975; 113: 653-655.
30. Roche M, Daly P, Crowley V, et al. A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole. Clin Exp Dermatol 2007; 32: 327-328.
31. Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 2002; 117: 779-795.
32. Malina L, Chlumsky J. A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. Acta Derm Venereol 1981; 61: 346-350.
33. Ashton RE, Hawk JL, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol 1984; 111: 609-613.
34. Valls V, Ena J, Enriquez de Salamanca R. Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. J Dermatol Sci 1994; 7: 169-175.
35. Kordac V, Martasek P, Kalab M, et al. [Chloroquine in the treatment of porphyria cutanea tarda symptomatica. Twelve years of experience in 307 patients]. Cas Lek Cesk 1981; 120: 1225-1227.
36. Kordac V, Jirsa M, Kotal P, et al. Agents affecting porphyrin formation and secretion: implications for porphyria cutanea treatment. Semin Hematol 1989; 26: 16-23.
37. Taljaard JJ, Shanley BC, Stewart-Wynne EG, et al. Studies on low-dose chloroquine therapy and the action of chloroquine in symptomatic porphyria. Br J Dermatol 1972; 87: 261-269.
38. Stolzel U, Kostler E, Schuppan D, et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003; 139: 309-313.
39. Kordac V, Papezova R, Semradova M. Chloroquine in the treatment of porphyria cutanea tarda. N Engl J Med 1977; 296: 949.
40. Malkinson FD, Levitt L. Hydroxychloroquine treatment of porphyria cutanea tarda. Arch Dermatol 1980; 116: 1147-1150.
41. Battle AM, Stella AM, De Kaminsky AR, et al. Two cases of infantile porphyria cutanea tarda: successful treatment with oral S-adenosyl-L-methionine and low-dose oral chloroquine. Br J Dermatol 1987; 116: 407-415.
42. Bruce AJ, Ahmed I. Childhood-onset porphyria cutanea tarda: successful therapy with low-dose hydroxychloroquine (Plaquenil). J Am Acad Dermatol 1998; 38: 810-814.
43. Kostler E, Wollina U. Therapy of porphyria cutanea tarda. Expert Opin Pharmacother 2005; 6: 377-383.
44. Egger NG, Goeger DE, Anderson KE. Effects of chloroquine in hematoporphyrin-treated animals. Chem Biol Interact 1996; 102: 69-78.
45. Scholnick PL, Epstein J, Marver HS. The molecular basis of the action of chloroquine in porphyria cutanea tarda. J Invest Dermatol 1973; 61: 226-232.
46. Kostler E, Pollack P, Seebacher C, et al. [Iron metabolism and chloroquine phosphate therapy in porphyria cutanea tarda]. Z Hautkr 1990; 65: 1030-1032.
47. Cainelli T, Di Padova C, Marchesi L, et al. Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda. Br J Dermatol 1983; 108: 593-600.
48. Felsher BF, Redeker AG. Effect of chloroquine on hepatic uroporphyrin metabolism in patients with porphyria cutanea tarda. Medicine (Baltimore) 1966; 45: 575-583.
49. Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment. Acta Derm Venereol 2007; 87: 401-405.
50. Thornsvard CT, Guider BA, Kimball DB. An unusual reaction to chloroquine-primaquine. JAMA 1976; 235: 1719-1720.
51. Liu AC. Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda. West J Med 1995; 162: 548-551.
52. Shanley BC, Taljaard JJ, Deppe WM, et al. Delta-aminolaevulinic acid in acute porphyria. S Afr Med J 1972; 46: 864.
53. Kordac V, Semradova M. Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol 1974; 90: 95-100.
54. Felson DT. Epidemiology of the rheumatic diseases. Curr Opin Rheumatol 1990; 2: 301-308.
55. Block JA. Hydroxychloroquine and retinal safety. Lancet 1998; 351: 771.
56. Rynes RI. Antimalarials. Is re-evaluation needed? J Clin Rheumatol 1998; 4: 50-51.
57. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109: 1377-1382.
58. Mascaro JM, Herrero C. New reasons for an archaic treatment: phlebotomy in sporadic porphyria cutanea tarda. Arch Dermatol 2003; 139: 379-380.
59. Ippen H. Treatment of porphyria cutanea tarda by phlebotomy. Semin Hematol 1977; 14: 253-259.
60. Poh-Fitzpatrick MB, Honig PJ, Kim HC, et al. Childhood-onset familial porphyria cutanea tarda: effects of therapeutic phlebotomy. J Am Acad Dermatol 1992; 27: 896-900.
61. Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95: 1565-1571.
62. Brissot P, Troadec MB, Bardou-Jacquet E, et al. Current approach to hemochromatosis. Blood Rev 2008; 22: 195-210.
63. Rocchi E, Gibertini P, Cassanelli M, et al. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med 1986; 107: 36-42.
64. Ratnaike S, Blake D, Campbell D, et al. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. Australas J Dermatol 1988; 29: 3-8.
65. Lundvall O. Phlebotomy treatment of porphyria cutanea tarda. Acta Derm Venereol Suppl (Stockh) 1982; 100: 107-118.
66. Kauppinen R, Timonen K, Mustajoki P. Treatment of the porphyrias. Ann Med 1994; 26: 31-38.
67. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1979; 67: 277-286.
68. Wennersten G, Ros AM. Chloroquine in treatment of porphyria cutanea tarda. Longterm efficacy of combined phlebotomy and high-dose chloroquine therapy. Acta Derm Venereol Suppl (Stockh) 1982; 100: 119-123.
69. Thomas CL, Badminton MN, Rendall JR, et al. Sclerodermatous changes of face, neck and scalp associated with familial porphyria cutanea tarda. Clin Exp Dermatol 2008; 33: 422-424.
70. Doyle JA, Friedman SJ. Porphyria and scleroderma: a clinical and laboratory review of 12 patients. Australas J Dermatol 1983; 24: 109-114.
71. Grossman ME, Poh-Fitzpatrick MB. Porphyria cutanea tarda. Diagnosis and management. Med Clin North Am 1980; 64: 807-827.
72. Chlumsky J, Malina L, Chlumska A. The effect of venesection therapy on liver tissue in porphyria cutanea tarda. Acta Hepatogastroenterol (Stuttg) 1973; 20: 124-130.
73. Cassiman D, Vannoote J, Roelandts R, et al. Porphyria cutanea tarda and liver disease. A retrospective analysis of 17 cases from a single center and review of the literature. Acta Gastroenterol Belg 2008; 71: 237-242.
74. Seubert S, Seubert A, Stella AM, et al. [Results of treatment of porphyria cutanea tarda with bloodletting and chloroquine]. Z Hautkr 1990; 65: 223-225.
75. Azim J, McCurdy H, Moseley RH. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. World J Gastroenterol 2008; 14: 5913-5915.
76. Alla V, Bonkovsky HL. Iron in non-hemochromatotic liver disorders. Semin Liver Dis 2005; 25: 461-472.
77. Rocchi E, Cassanelli M, Borghi A, et al. Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda. Dermatologica 1991; 182: 27-31.
78. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107: 3436-3441.
79. Hazin R, Abu-Rajab Tamimi TI, Abuzetun JY, et al. Recognizing and treating cutaneous signs of liver disease. Cleve Clin J Med 2009; 76: 599-606.
80. Vanorden HE, Hagemann TM. Deferasirox - an oral agent for chronic iron overload. Ann Pharmacother 2006; 40: 1110-1117.
81. Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005; 18: 289-298.
82. Toll A, Celis R, Ozalla MD, et al. Hemochromatosis gene mutations and response to chloroquine in sporadic porphyria cutanea tarda. Acta Derm Venereol 2006; 86: 279-280.
83. Roberts AG, Whatley SD, Morgan RR, et al. Increased frequency of the hemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321-323.
84. Santos M, Clevers HC, Marx JJ. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. N Engl J Med 1997; 336: 1327-1328.
85. Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in the hemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28: 404-409.
86. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661-1669.
87. Bardia A, Swanson EA, Thomas KG. 66-year-old woman with painless vesicular lesions. Mayo Clin Proc 2009; 84: 639-642.
88. Altiparmak UE, Oflu Y, Kocaoglu FA, et al. Ocular complications in two cases with porphyria. Cornea 2008; 27: 1093-1096.
89. Tsambaos D, Bolsen K, Georgiou S, et al. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene. Arch Dermatol Res 1994; 286: 347-349.
90. Monastirli A, Georgiou S, Bolsen K, et al. Treatment of porphyria cutanea tarda with oral thalidomide. Skin Pharmacol Appl Skin Physiol 1999; 12: 305-311.
91. Horie Y, Tanaka K, Okano J, et al. Cimetidine in the treatment of porphyria cutanea tarda. Intern Med 1996; 35: 717-719.
92. Murty HS, Nair PP. Prevention of allylisopropylacetamide-induced experimental porphyria in the rat by vitamin E. Nature 1969; 223: 200-201.
93. Pinelli A, Trivulzio S, Tomasoni L, et al. High-dose vitamin E lowers urine porphyrin levels in patients affected by porphyria cutanea tarda. Pharmacol Res 2002; 45: 355-359.
94. Nair PP, Murty HS, Grossman NR. The in vivo effect of vitamin E in experimental porphyria. Biochim Biophys Acta 1970; 215: 112-118.
95. Ayres S Jr, Mihan R. Porphyria cutanea tarda: response to vitamin E. A review and two case reports. Cutis 1978; 22: 50-52.
96. Nair PP, Mezey E, Murty HS, et al. Vitamin E and porphyrin metabolism in man. Arch Intern Med 1971; 128: 411-415.
97. Szekely E, Vereckei A, Almasi A, et al. Effects of vitamin E administration on the hemorheological status and redox homeostasis of patients with porphyria cutanea tarda treated with phlebotomy. Clin Hemorheol Microcirc 2007; 36: 13-23.
98. Mascaro JM. Porphyria cutanea tarda: clinical manifestations. Curr Probl Dermatol 1991; 20: 79-90.
99. Mascaro JM. Porphyrias in children. Pediatr Dermatol 1992; 9: 371-372.
100. Welland FH, Carlsen RA. Porphyria cutanea tarda in an 8-year-old boy. Arch Dermatol 1969; 99: 451-454.
101. Charlton V, Phibbs R. Peripheral venous partial exchange transfusions for neonatal polycythemia. Clin Pediatr (Phila) 1983; 22: 59-60.
102. Storck H, Schwarz K, Ott F. [A case of porphyria cutanea tarda in a 5-year-old child]. Bull Soc Fr Dermatol Syphiligr 1972; 79: 240-242.
103. Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 1993; 28: 764-770.
104. Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 2007; 45: 1306-1312.
105. Munoz JJ, Roca C, Santos JL, et al. Effect of zinc or S-adenosyl-L-methionine on longterm administration of low doses of lead to rats. Pharmacol Toxicol 1993; 73: 189-191.
106. Poh-Fitzpatrick MB, Wang X, Anderson KE, et al. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Dermatol 2002; 46: 861-866.
107. Paredes SR, Kozicki PA, Battle AM. S-adenosyl-L-methionine: a counter to lead intoxication? Comp Biochem Physiol B 1985; 82: 751-757.
108. Hebert AA, Farmer KL, Poh-Fitzpatrick MB. Peritoneal dialysis does not reduce serum porphyrin levels in porphyria cutanea tarda. Nephron 1992; 60: 240.
109. Anderson KE, Goeger DE, Carson RW, et al. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on longterm hemodialysis. N Engl J Med 1990; 322: 315-317.
110. Yaqoob M, Smyth J, Ahmad R, et al. Hemodialysis-related porphyria cutanea tarda and treatment by recombinant human erythropoietin. Nephron 1992; 60: 428-431.
111. Peces R, Enriquez de Salamanca R, Fontanellas A, et al. Successful treatment of hemodialysis-related porphyria cutanea tarda with erythropoietin. Nephrol Dial Transplant 1994; 9: 433-435.
112. Carson RW, Dunnigan EJ, DuBose TD Jr, et al. Removal of plasma porphyrins with high-flux hemodialysis in porphyria cutanea tarda associated with end-stage renal disease. J Am Soc Nephrol 1992; 2: 1445-1450.
113. Disler P, Day R, Burman N, et al. Treatment of hemodialysis-related porphyria cutanea tarda with plasma exchange. Am J Med 1982; 72: 989-993.
114. Gross U, Hoffmann GF, Doss MO. Erythropoietic and hepatic porphyrias. J Inherit Metab Dis 2000; 23: 641-661.
115. Siersema PD, ten Kate FJ, Mulder PG, et al. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 1992; 12: 56-61.
116. Okano J, Horie Y, Kawasaki H, et al. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44: 525-528.
117. Siegel LB, Eber BB. Porphyria cutanea tarda remission. Ann Intern Med 1994; 121: 308-309.
118. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci 1998; 43: 529-533.
119. Takikawa H, Yamazaki R, Shoji S, et al. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995; 22: 249-250.
120. Fernandez I, Castellano G, Enriquez de Salamanca R, et al. Porphyria cutanea tarda as a predictor of poor response to interferon-alpha therapy in chronic hepatitis C. Scand J Gastroenterol 2003; 38: 314-319.
121. Furuta M, Kaito M, Gabazza E, et al. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol 2000; 35: 60-62.
122. Jessner W, Der-Petrossian M, Christiansen L, et al. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology 2002; 36: 1301-1302.
123. Frider B, Buonsante ME, Tiscornia J, et al. [Development of porphyria cutanea tarda in a chronic hepatitis C patient with indetectable viremia under treatment with peg-interferon plus ribavirin]. Acta Gastroenterol Latinoam 2006; 36: 38-41.
124. Bilo L, Meo R, Fulvia de Leva M. Levetiracetam in idiopathic generalized epilepsy and porphyria cutanea tarda. Clin Drug Investig 2006; 26: 357-359.
125. Hickman G, Duval A, Picard C, et al. [Porphyria cutanea tarda revealed by voriconazole]. Ann Dermatol Venereol 2010; 137: 36-39.
126. Bertoli LF, Barton JC. Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer. Clin Breast Cancer 2007; 7: 716-718.
127. Cabanillas M, Peteiro C, Toribio J. Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib? Dermatology 2006; 213: 246-247.
128. Ho AY, Deacon A, Osborne G, et al. Precipitation of porphyria cutanea tarda by imatinib mesylate? Br J Haematol 2003; 121: 375.
129. Celesia BM, Onorante A, Nunnari G, et al. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report. AIDS 2007; 21: 1495-1496.
130. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 1992; 71: 1-13.
131. Shehan JM, Huerter CJ. Porphyria cutanea tarda associated with an acute gastrointestinal bleed: the roles of supplemental iron and blood transfusion. Cutis 2001; 68: 147-150.
132. Herbert V, Shaw S, Jayatilleke E. Vitamin C-driven free radical generation from iron. J Nutr 1996; 126(Suppl.): 1213-1220.
133. Kauppinen R. Porphyrias. Lancet 2005; 365: 241-252.
134. Kauppinen R. Management of the acute porphyrias. Photodermatol Photoimmunol Photomed 1998; 14: 48-51.
135. Whatley SD, Puy H, Morgan RR, et al. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet 1999; 65: 984-994.
136. Lamoril J, Puy H, Whatley SD, et al. Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria. Am J Hum Genet 2001; 68: 1130-1138.
137. Moore M, McColl KEL, Rimington C, et al. Disorders of Porphyrin Metabolism, 1st edn. New York: Plenum Medical Book Co., 1987.
138. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142: 439-450.
139. Anderson KE, Spitz IM, Bardin CW, et al. A gonadotropin-releasing hormone analog prevents cyclical attacks of porphyria. Arch Intern Med 1990; 150: 1469-1474.
140. Anderson KE. LHRH analogs for hormonal manipulation in acute intermittent porphyria. Semin Hematol 1989; 26: 10-15.
141. Perlroth MG, Marver HS, Tschudy DP. Oral contraceptive agents and the management of acute intermittent porphyria. JAMA 1965; 194: 1037-1042.
142. Innala E, Backstrom T, Bixo M, et al. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand 2010; 89: 95-100.
143. Lamon JM, Frykholm BC, Hess RA, et al. Hematin therapy for acute porphyria. Medicine (Baltimore) 1979; 58: 252-269.
144. Anderson E. The porphyrias. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine, 21st edn. Philadelphia, PA: W. B. Saunders Co., 2000; 1123-1130.
145. Andant C, Puy H, Bogard C, et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000; 32: 933-939.
146. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 1996; 240: 195-201.
147. Chemmanur AT, Bonkovsky HL. Hepatic porphyrias: diagnosis and management. Clin Liver Dis 2004; 8: 807-838.
148. Harper P, Sardh E, Henrichson A. Plasma porphyrin precursors and porphyrins in AIP patients with chronic renal failure. In: Porphyrins and Porphyrias International Meeting, April 29-May 3 2007, Rotterdam, the Netherlands.
149. Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004; 363: 705-706.
150. Johansson A, Nowak G, Moller C, et al. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria. Mol Ther 2004; 10: 337-343.
151. Todd DJ. Erythropoietic protoporphyria. Br J Dermatol 1994; 131: 751-766.
152. Minder EI, Schneider-Yin X, Steurer J, et al. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009; 55: 84-97.
153. Krook G, Haeger-Aronsen B. Beta-carotene in the treatment of erythropoietic protoporphyria. A short review. Acta Derm Venereol Suppl (Stockh) 1982; 100: 125-129.
154. Minder EI, Schneider-Yin X, Minder CE. Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal. Health Qual Life Outcomes 2010; 8: 60.
155. Britton G. Structure and properties of carotenoids in relation to function. FASEB J 1995; 9: 1551-1558.
156. Eves PC, MacNeil S, Haycock JW. Alpha-melanocyte stimulating hormone, inflammation and human melanoma. Peptides 2006; 27: 444-452.
157. Catania A, Gatti S, Colombo G, et al. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004; 56: 1-29.
158. Bustamante J, Bredeston L, Malanga G, et al. Role of melanin as a scavenger of active oxygen species. Pigment Cell Res 1993; 6: 348-353.
159. Kadekaro AL, Wakamatsu K, Ito S, et al. Cutaneous photoprotection and melanoma susceptibility: reaching beyond melanin content to the frontiers of DNA repair. Front Biosci 2006; 11: 2157-2173.
160. Mathews-Roth MM. Treatment of the cutaneous porphyrias. Clin Dermatol 1998; 16: 295-298.
161. de Rooij FWM, Wilson JHP. Porphyria: a diagnostic approach. In: Kadish KM, Smith KM, Guilard R, eds. The Porphyrin Handbook. New York: Elsevier Science, 2003; 211-245.
162. Corbett MF, Herxheimer A, Magnus IA, et al. The longterm treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 1977; 97: 655-662.
163. Norris PG, Baker CS, Roberts JE, et al. Treatment of erythropoietic protoporphyria with N-acetylcysteine. Arch Dermatol 1995; 131: 354-355.
164. Roelandts R. Photo(chemo)therapy and general management of erythropoietic protoporphyria. Dermatology 1995; 190: 330-331.
165. Collins P, Ferguson J. Narrowband UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995; 132: 956-963.
166. Roelandts R. Phototherapy of photodermatoses. J Dermatolog Treat 2002; 13: 157-160.
167. Warren LJ, George S. Erythropoietic protoporphyria treated with narrowband (TL-01) UVB phototherapy. Australas J Dermatol 1998; 39: 179-182.
168. Mathews-Roth MM, Rosner B. Longterm treatment of erythropoietic protoporphyria with cysteine. Photodermatol Photoimmunol Photomed 2002; 18: 307-309.
169. Mathews-Roth MM, Rosner B, Benfell K, et al. A double-blind study of cysteine photoprotection in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 1994; 10: 244-248.
170. Bijlmer-Iest JC, Baart de la Faille H, Van Asbeck BS, et al. Protoporphyrin photosensitivity cannot be attenuated by oral N-acetylcysteine. Photodermatol Photoimmunol Photomed 1992; 9: 245-249.
171. Leone N, Marzano A, Cerutti E, et al. Liver transplantation for erythropoietic protoporphyria: report of a case with medium-term follow-up. Dig Liver Dis 2000; 32: 799-802.
172. Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 2007; 10: 444-455.
173. Thunell S, Harper P. Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda - suggestions for a handling program. Scand J Clin Lab Invest 2000; 60: 561-579.
174. Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. Postgrad Med J 2007; 83: 739-748.
175. Gorchein A, Foster GR. Liver failure in protoporphyria: longterm treatment with oral charcoal. Hepatology 1999; 29: 995-996.
176. Meerman L. Erythropoietic protoporphyria. An overview with emphasis on the liver. Scand J Gastroenterol Suppl 2000; 232: 79-85.
177. Samuel D, Boboc B, Bernuau J, et al. Liver transplantation for protoporphyria. Evidence for the predominant role of the erythropoietic tissue in protoporphyrin overproduction. Gastroenterology 1988; 95: 816-819.
178. McGuire BM, Bonkovsky HL, Carithers RL Jr, et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005; 11: 1590-1596.
179. Meerman L, Verwer R, Slooff MJ, et al. Perioperative measures during liver transplantation for erythropoietic protoporphyria. Transplantation 1994; 57: 155-158.
180. Do KD, Banner BF, Katz E, et al. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 2002; 73: 469-472.
181. Potter C, Tolaymat N, Bobo R, et al. Hematin therapy in children with protoporphyric liver disease. J Pediatr Gastroenterol Nutr 1996; 23: 402-407.
182. Reichheld JH, Katz E, Banner BF, et al. The value of intravenous heme-albumin and plasmapheresis in reducing postoperative complications of orthotopic liver transplantation for erythropoietic protoporphyria. Transplantation 1999; 67: 922-928.
183. Muley SA, Midani HA, Rank JM, et al. Neuropathy in erythropoietic protoporphyrias. Neurology 1998; 51: 262-265.
184. Wahlin S, Aschan J, Bjornstedt M, et al. Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 2007; 46: 174-179.
185. Rand EB, Bunin N, Cochran W, et al. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 2006; 118: 1896-1899.
186. Lim HW. Pathophysiology of cutaneous lesions in porphyrias. Semin Hematol 1989; 26: 114-119.
187. Farr PM, Diffey BL, Matthews JN. Inhibition of photosensitivity in erythropoietic protoporphyria with terfenadine. Br J Dermatol 1990; 122: 809-815.
188. Wahlin S, Floderus Y, Stal P, et al. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med 2010; 269: 278-288.
189. Ross JB, Moss MA. Relief of the photosensitivity of erythropoietic protoporphyria by pyridoxine. J Am Acad Dermatol 1990; 22: 340-342.
190. Winship I, Ross G, Nioll A, et al. Antioxidant effect of warfarin therapy: a possible symptomatic treatment for erythropoietic protoporphyria. Arch Dermatol 2009; 145: 960-961.
191. Boffa MJ, Ead RD, Reed P, et al. A double-blind, placebo-controlled, crossover trial of oral vitamin C in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 1996; 12: 27-30.
192. Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. Gut 2007; 56: 1009-1018.
193. Bloomer JR, Pierach CA. Effect of hematin administration to patients with protoporphyria and liver disease. Hepatology 1982; 2: 817-821.
194. Pascual C, Gonzalez R, Torricella RG. Scavenging action of propolis extract against oxygen radicals. J Ethnopharmacol 1994; 41: 9-13.
195. Schoemaker JH, Bousema MT, Zijlstra H, et al. Treatment of erythropoietic protoporphyria with hydroxyethylrutosides. Dermatology 1995; 191: 36-38.
196. Holme SA, Thomas CL, Whatley D, et al. Symptomatic response of erythropoietic protoporphyria to iron supplementation. J Am Acad Dermatol 2007; 56: 1070-1072.
197. McClements BM, Bingham A, Callender ME, et al. Erythropoietic protoporphyria and iron therapy. Br J Dermatol 1990; 122: 423-424.
198. Milligan A, Graham-Brown RA, Sarkany I, et al. Erythropoietic protoporphyria exacerbated by oral iron therapy. Br J Dermatol 1988; 119: 63-66.
199. Yamamoto S, Hirano Y, Horie Y. Cimetidine reduces erythrocyte protoporphyrin in erythropoietic protoporphyria. Am J Gastroenterol 1993; 88: 1465-1466.
200. Chakrabarti A, Tan CY. Dietary fish oils as a therapeutic option in erythropoietic protoporphyria. Clin Exp Dermatol 2002; 27: 324-327.
201. Ged C, Megarbane H, Chouery E, et al. Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling. J Invest Dermatol 2004; 123: 589-591.
202. Puy H, Gouya L, Deybach JS. Porphyrias. Lancet 2010; 375: 924-937.
203. Piomelli S, Poh-Fitzpatrick MB, Seaman C, et al. Complete suppression of the symptoms of congenital erythropoietic porphyria by longterm treatment with high-level transfusions. N Engl J Med 1986; 314: 1029-1031.
204. Haining RG, Cowger ML, Labbe RF, et al. Congenital erythropoietic porphyria. II. The effects of induced polycythemia. Blood 1970; 36: 297-309.
205. Rosenthal IM, Lipton EL, Asrow G. Effect of splenectomy on porphyria erythropoietica. Pediatrics 1955; 15: 663-675.
206. Kaufman BM, Vickers HR, Rayne J, et al. Congenital erythropoietic porphyria. Report of a case. Br J Dermatol 1967; 79: 210-220.
207. Simard H, Barry A, Villeneuve B, et al. [Congenital erythropoietic porphyria]. Can Med Assoc J 1972; 106: 1002 passim.
208. Kauffman L, Evans DI, Stevens RF, et al. Bone marrow transplantation for congenital erythropoietic porphyria. Lancet 1991; 337: 1510-1511.
209. Faraci M, Morreale G, Boeri E, et al. Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. Pediatr Transplant 2008; 12: 117-120.
210. Zix-Kieffer I, Langer B, Eyer D, et al. Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease). Bone Marrow Transplant 1996; 18: 217-220.
211. Shaw PH, Mancini AJ, McConnell JP, et al. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 2001; 27: 101-105.
212. Thomas C, Ged C, Nordmann Y, et al. Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr 1996; 129: 453-456.
213. Taibjee SM, Stevenson OE, Abdullah A, et al. Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma. Br J Dermatol 2007; 156: 567-571.
214. Oliveri MB, Mautalen C, Mega M, et al. Congenital erythropoietic porphyria: skeletal manifestations and effect of pamidronate treatment. Bone 1994; 15: 101-104.
215. Pullon HW, Bellingham AJ, Humphreys S, et al. The osteodystrophy of congenital erythropoietic porphyria. Bone 1991; 12: 89-92.
216. Pimstone NR. Roles and pitfalls of transplantation in human porphyria. Liver Transpl 2005; 11: 1460-1462.
217. Pimstone NR, Gandhi SN, Mukerji SK. Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 1987; 316: 390-393.
218. Minder EI, Schneider-Yin X, Moll F. Lack of effect of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 1994; 330: 1092-1094.
219. Gorchein A, Guo R, Lim CK, et al. Porphyrins in urine, plasma, erythrocytes, bile and feces in a case of congenital erythropoietic porphyria (Gunther's disease) treated with blood transfusion and iron chelation: lack of benefit from oral charcoal. Biomed Chromatogr 1998; 12: 350-356.
220. Tanigawa K, Namba H, Ohtsuru A, et al. Plasmasorbent therapy with activated charcoal column for congenital erythropoietic porphyria. Dermatology 1994; 188: 329-330.
221. Guarini L, Piomelli S, Poh-Fitzpatrick MB. Hydroxyurea in congenital erythropoietic porphyria. N Engl J Med 1994; 330: 1091-1092.
222. Fritsch C, Bolsen K, Ruzicka T, et al. Congenital erythropoietic porphyria. J Am Acad Dermatol 1997; 36: 594-610.
223. Robert-Richard E, Moreau-Gaudry F, Lalanne M, et al. Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. Am J Hum Genet 2008; 82: 113-124.
224. Christiansen L, Ged C, Hombrados I, et al. Screening for mutations in the uroporphyrinogen decarboxylase gene using denaturing gradient gel electrophoresis. Identification and characterization of six novel mutations associated with familial PCT. Hum Mutat 1999; 14: 222-232.
225. Gallicchio L, Boyd K, Matanoski G, et al. Carotenoids and the risk of developing lung cancer: a systematic review. Am J Clin Nutr 2008; 88: 372-383.
226. Al-Wadei HA, Schuller HM. Beta-Carotene promotes the development of NNK-induced small airway-derived lung adenocarcinoma. Eur J Cancer 2009; 45: 1257-1264.
227. de Verneuil H, Robert-Richard E, Ged C. Successful gene therapy of mice with congenital erythropoietic porphyria. Med Sci (Paris) 2008; 24: 615-620.